![](/img/cover-not-exists.png)
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Boyiadzis, Michael M., Kirkwood, John M., Marshall, John L., Pritchard, Colin C., Azad, Nilofer S., Gulley, James L.Volume:
6
Language:
english
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1186/s40425-018-0342-x
Date:
December, 2018
File:
PDF, 902 KB
english, 2018